title: Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
abstract: Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren's syndrome that occasionally associated with malignancies. PUF60 is identical with far-upstream element-binding protein-interacting repressor (FIR) that is a transcriptional repressor of c-myc gene. In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRΔexon2) is overexpressed as a dominant negative form of FIR. In this study, to reveal the presence and the significance of anti-FIRs (FIR/FIRΔexon2) antibodies in cancers were explored in the sera of colorectal and other cancer patients. Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera (Mann-Whitney U test, p < 0.01). The level of anti-FIRs antibodies significantly decreased after the operation (p < 0.01). Anti-FIRs antibodies were detected in the sera of early-stage and/or recurrent colon cancer patients in which anti-p53 antibodies, CEA, and CA19-9 were not detected as well as in the sera of other cancer patients. Furthermore, the area under the curve of receiver operating characteristic for anti-FIRs antibodies was significantly larger (0.85) than that for anti-p53 antibodies or CA19-9. In conclusions, the combination of anti-FIRs antibodies with other clinically available tumor markers further improved the specificity and accuracy of cancer diagnosis.
authors.affiliation: Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan.
authors.forename: Sohei
authors.initials: S
authors.lastname: Kobayashi
authors.affiliation: Department of Physical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan.
authors.forename: Tyuji
authors.initials: T
authors.lastname: Hoshino
authors.affiliation: Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
authors.forename: Takaki
authors.initials: T
authors.lastname: Hiwasa
authors.affiliation: Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan.
authors.forename: Mamoru
authors.initials: M
authors.lastname: Satoh
authors.affiliation: Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan.|Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan.
authors.forename: Bahityar
authors.initials: B
authors.lastname: Rahmutulla
authors.affiliation: Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan.
authors.forename: Sachio
authors.initials: S
authors.lastname: Tsuchida
authors.affiliation: Department of Physical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Komukai
authors.affiliation: Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Department of Academic Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
authors.affiliation: Department of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo 143-8541, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.affiliation: Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan.
authors.forename: Fumio
authors.initials: F
authors.lastname: Nomura
authors.affiliation: Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan.|Department of Laboratory Medicine & Division of Clinical Genetics and Proteomics Chiba University Hospital, Chiba 260-8670, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Matsushita
mesh_terms: D019540:Area Under Curve; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D003082:Colectomy; D003110:Colonic Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D006801:Humans; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D000072260:RNA Splicing Factors / Q000276:immunology*; D012372:ROC Curve; D012097:Repressor Proteins / Q000276:immunology*; D015203:Reproducibility of Results; D012698:Serologic Tests; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D000072260:RNA Splicing Factors; D012097:Repressor Proteins; C410595:poly-U binding splicing factor 60KDa
keywords: auto-antibodies; cancer biomarker; colorectal cancer; far-upstream element-binding protein-interacting repressor (FIR) = poly(U)-binding-splicing factor (PUF60)